Filter sub products categories alphabetically
Ziprasidone belongs to a class of medications known as typical antipsychotics, which are generally used to treat schizophrenia and manic depression. Schizophrenia is a mental illness in which a person may feel, hear, or see things that are not there, believe falsehoods, and have extraordinary suspicion or confusion. Manic depression, often known as bipolar illness, is a significant brain condition characterized by strong mood swings as well as frequent mood and behavioral changes. It works by suppressing the effects of chemical messengers in the brain, improving thinking, mood, and behavior; it promotes clear thinking and reduces hallucinations. It is used to treat manic periods of bipolar illness as well as agitation in schizophrenia. The FDA authorized Ziprasidone in 2001.
BRAND NAMES
Zeldox –It contains the active ingredients of Ziprasidone. It is available in the form of tablets used to treat schizophrenia and bipolar disorder.
Geodon- It contains the active ingredients of Ziprasidone. It is available in the form of capsules.
MECHANISM OF ACTION
Ziprasidone is an atypical antipsychotic that binds to dopaminergic, serotonergic, adrenergic, and histamine receptors. It also shows minimal action on the norepinephrine and serotonin transporters. Antagonizing histaminergic and adrenergic receptors can cause drowsiness and orthostatic hypotension. In terms of schizophrenia therapy, antagonism of the dopamine receptor in the mesolimbic pathways is effective in reducing positive symptoms, but antagonism of the 5H2A receptor in the mesocortical route reduces negative symptoms of psychosis. The drug's effectiveness and mode of action for treating bipolar disorder remain uncertain.
PHARMACOKINETICS
Absorption
Oral formation Tmax is around 6 to 8 hours. Within 1 to 3 days of treatment, plasma concentrations reach steady-state levels. When taken orally with meals, the bioavailability is around 70 percent. IM dosing provides close to 100% bioavailability. The IM formulation shortens the time required to achieve peak plasma concentration.
Distribution
Ziprasidone's mean apparent volume of distribution is 1.5 liters per kilogram.
Metabolism
Glutathione and aldehyde oxidase mediate the major metabolism of ziprasidone; CYP1A2 and CYP3A4 play a small part in this process. Benzothiazole sulfoxide and benzothiazole sulfone are among the active metabolites produced.
Excretion
A minimal amount of Ziprasidone is excreted in the urine.
PHARMACODYNAMICS
Ziprasidone acted as an antagonist at the D2, 5H2A, and 5HT1D receptors and an agonist at the 5HT1A receptor. Ziprasidone decreased serotonin and norepinephrine reuptake at synapses. Other receptor/binding sites tested showed no significant affinity, including the cholinergic muscarinic receptor.
DOSAGE AND ADMINISTRATION
DRUG INTERACTIONS
Drug interactions with ziprasidone may include
CONTRAINDICATIONS
Patients having a recent acute myocardial infarction. Patients have a prior history of QT prolongation, including congenital long QT syndrome. Patients with uncompensated cardiac failure.
SIDE EFFECTS
Ziprasidone may cause side effects
Some side effects can be serious
OVERDOSE
Symptoms of overdose may include the following
TOXICITY
Ziprasidone has a binding affinity for histamine H1 receptors, which can cause somnolence, especially at hazardous doses. Priapism, body temperature regulation, and suicide can all result from hazardous medication levels if proper patient and case management is done. An overdose ensures the patient's breathing, and intubation may be required. If the patient is unconscious, IV access is essential for doing gastric lavage intubation. Charcoal can also be used in conjunction with a laxative to help with medication clearance.